There is a significant correlation between MNK1 high expression and unfavorable overall survival in kidney, liver and prostate cancer and between MNK2 high expression and unfavorable overall survival in low grade glioma and prostate cancer patients (Figure 3). Here, MKNK2 is linked to prostate carcinoma.